AI called the ‘perfect tool’ to flag signs of serious trouble ahead for new COVID patients

An experimental set of algorithms has achieved accuracy of 70% to 80% at predicting which of 53 COVID-positive patients at two hospitals in China would get the sickest.

While the proof-of-concept performance is about on par with other published uses of AI in medicine, the developers in this case are focusing on COVID-19—and presenting their work directly to a consumer audience.

Writing in the global newsroom network The Conversation, lead investigators Megan Coffee, MD, PhD, and Anasse Bari, PhD, report they’re now working with bigger datasets from multiple sources.

Coffee is an infectious-disease specialist, Bari a computer scientist. Both are with New York University.

“AI, which can recognize many elusive patterns simultaneously, is the perfect tool to help doctors identify high-risk patients early,” they comment. “This gives them time to better prepare for these cases and could save lives.”

The tool also found strong predictors of worsening disease in combinations of body aches, slightly elevated liver enzymes and raised hemoglobin levels.

In a normal setting, doctors wouldn’t be much concerned by these symptoms and readings, the authors note.

Their next objective is to make their tool more accurate and broadly applicable by training the algorithms on data from multiple medical centers.

“While the AI we designed is only a first test, the results are extremely encouraging,” Coffee and Bari write. “We believe AI has a role to play in fighting this pandemic and hope to soon put our system to work helping doctors on the front lines.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”